Navigation Links
CoreLab Partners Opens Office in Tokyo, Japan

PRINCETON, N.J., Jan. 17, 2012 /PRNewswire/ -- Signaling a further commitment to expand its business model in the Pacific Rim and building a global presence as one of the largest imaging and cardiac safety core labs in the world, CoreLab Partners, Inc. today has announced the opening of an office in Tokyo, Japan under the wholly owned subsidiary of CoreLab Partners Japan, K.K.

"We are pleased to announce the creation of our new subsidiary in Asia corresponding with the opening of an office in central Tokyo," said CoreLab Partners' President and Chief Executive Officer, Dr. Mike Woehler. "This expanded presence is a natural extension of our geographic reach and global strategy to serve our growing base of multinational biopharma companies operating in the region and will complement our operational capability, which was established in Shanghai, China, over a decade ago," added Woehler.

CoreLab Partners currently has a strong business alliance in Japan with Suzuken Co. Ltd., which markets its cardiac safety services; this new presence is designed to further establish the global brand in the Pacific Rim and expand their full line of imaging sciences capabilities in Southeast Asia. "CoreLabs has been present in the region since 1999 and has conducted hundreds of drug development studies in both cardiac safety and imaging for a variety of sponsor partners. The addition of a local Regional Director and Business Development professional will allow CoreLab Partners to better service our client base by nurturing current relationships and opening up new markets for our full line of cardiac safety and imaging services," said Kevin Duffy, Vice President, Global Business Development.

About CoreLab Partners, Inc.

CoreLab Partners, with offices in North America, Europe and Asia, provides comprehensive medical image assessment and cardiac safety services to the pharmaceutical, biotechnology and medical device industries. An efficient operational process facilitates successful new drug development programs by employing an experienced clinical operations team combined with board certified, sub-specialty trained Radiologists, Cardiologists, nuclear medicine physicians and Oncologists. CoreLab Partners delivers disciplined solutions for the collection, analysis and management of patient images and cardiac safety & efficacy information during drug development. Driven by best-in-class science, emerging technologies and service quality, CoreLabs is a global leader providing imaging sciences in all major modalities complemented by service offerings in the conduct of automated ECG, Thorough QT, Holter Monitoring, Ambulatory Blood Pressure Monitoring and Pulse Wave Analysis.

Kevin D. Duffy
Vice President, Global Business Development
Phone: 609-936-2600

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE CoreLab Partners, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CoreLab Partners Completes First TQT Study in Japan
2. CoreLab Partners Launches New DXA Imaging Service Offerings
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Mentice, Inc. and the Milwaukee Area Technical College (MATC) Announce Their Partnership in the Area of Procedural Medical Simulation
6. Catalyst Pharmaceutical Partners Reports Second Quarter 2008 Financial Results
7. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
8. Oridion Expands its OEM Partnerships - New Agreement with Spacelabs Healthcare
9. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
10. Varian, Inc. to Present at Thomas Weisel Partners 2008 Healthcare Conference
11. Thermage, Inc. to Present at the 2008 Thomas Weisel Partners Healthcare Conference
Post Your Comments:
(Date:6/24/2016)... , ... June 24, 2016 , ... While the majority ... as the Cary 5000 and the 6000i models are higher end machines that use ... height of the spectrophotometer’s light beam from the bottom of the cuvette holder. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... the release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” ... and retention in this eBook by providing practical tips, tools, and strategies for ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 Favorable ... Election Administration and Criminal Identification to Boost Global Biometrics ... recently released TechSci Research report, " Global Biometrics Market ... Competition Forecast and Opportunities, 2011 - 2021", the global ... by 2021, on account of growing security concerns across ...
(Date:5/12/2016)... -- , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
Breaking Biology News(10 mins):